Multivariate hazards for transplantation outcomes in patients with AML, based on donor KIR3DL1 inhibition potential
| . | OS . | . | EFS . | . | Relapse . | . |
|---|---|---|---|---|---|---|
| . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| KIR3DL1-Weak Inhibiting | Reference | Reference | Reference | |||
| KIR3DL1-Noninteracting | 1.83 (0.94-3.56) | .077 | 2.14 (1.16-3.95) | .015 | 2.97 (1.33-6.64) | .008 |
| KIR3DL1-Strong Inhibiting | 1.4 (0.67-2.94) | .367 | 1.6 (0.81-3.17) | .174 | 1.65 (0.66-4.08) | .281 |
| . | OS . | . | EFS . | . | Relapse . | . |
|---|---|---|---|---|---|---|
| . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| KIR3DL1-Weak Inhibiting | Reference | Reference | Reference | |||
| KIR3DL1-Noninteracting | 1.83 (0.94-3.56) | .077 | 2.14 (1.16-3.95) | .015 | 2.97 (1.33-6.64) | .008 |
| KIR3DL1-Strong Inhibiting | 1.4 (0.67-2.94) | .367 | 1.6 (0.81-3.17) | .174 | 1.65 (0.66-4.08) | .281 |